Myovant Sciences Ltd (NASDAQ:MYOV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “
Separately, Evercore ISI began coverage on shares of Myovant Sciences in a report on Wednesday, August 16th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $18.20.
Shares of Myovant Sciences (NASDAQ MYOV) opened at 13.95 on Friday. The firm’s market capitalization is $848.77 million. The company has a 50-day moving average price of $11.51 and a 200 day moving average price of $11.91. Myovant Sciences has a 12-month low of $9.92 and a 12-month high of $15.50.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/27/myovant-sciences-ltd-myov-stock-rating-upgraded-by-zacks-investment-research.html.
Several hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new stake in Myovant Sciences during the second quarter worth approximately $648,000. RA Capital Management LLC increased its stake in Myovant Sciences by 19.6% in the second quarter. RA Capital Management LLC now owns 2,807,550 shares of the company’s stock worth $32,848,000 after buying an additional 459,128 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Myovant Sciences during the second quarter worth approximately $174,000. Voya Investment Management LLC increased its stake in Myovant Sciences by 5.4% in the second quarter. Voya Investment Management LLC now owns 421,397 shares of the company’s stock worth $4,931,000 after buying an additional 21,478 shares during the last quarter. Finally, OxFORD Asset Management LLP increased its stake in Myovant Sciences by 15.4% in the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock worth $348,000 after buying an additional 3,971 shares during the last quarter.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
